4//SEC Filing
Laliberte Kevin 4
Accession 0001562180-19-005055
CIK 0001685071other
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 4:20 PM ET
Size
6.7 KB
Accession
0001562180-19-005055
Insider Transaction Report
Form 4
Laliberte Kevin
Sr. VP, Product Development
Transactions
- Sale
Common Stock
2019-09-30$28.00/sh−3,100$86,800→ 5,357 total - Sale
Common Stock
2019-09-30$28.00/sh−596$16,688→ 4,761 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan based on a limit price order adopted by the Reporting Person.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units.
Documents
Issuer
Dova Pharmaceuticals Inc.
CIK 0001685071
Entity typeother
Related Parties
1- filerCIK 0001709417
Filing Metadata
- Form type
- 4
- Filed
- Oct 1, 8:00 PM ET
- Accepted
- Oct 2, 4:20 PM ET
- Size
- 6.7 KB